Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

SUNG-HSIN KUOTseng, Ling-MingLing-MingTsengChen, Shou-TungShou-TungChenSagara, YasuakiYasuakiSagaraChang, Yuan-ChingYuan-ChingChangYeh, Hsien-TangHsien-TangYehKuo, Yao-LungYao-LungKuoHung, Chih-ChiangChih-ChiangHungTZU-PIN LULee, Yi-HsuanYi-HsuanLeeToi, MasakazuMasakazuToiCHIUN-SHENG HUANG2023-10-052023-10-052023-09-141471-2407https://scholars.lib.ntu.edu.tw/handle/123456789/635941Radiotherapy (RT) following breast-conserving surgery (BCS) is mainly used to decrease the rate of ipsilateral breast tumor recurrence (IBTR) in women with breast ductal carcinoma in situ (DCIS). Recent studies have demonstrated that low-dose tamoxifen significantly reduces IBTR in breast DCIS. Here, we aim to determine whether the administration of low-dose tamoxifen is non-inferior to RT in preventing IBTR in patients with low-risk characteristics of breast DCIS.enBreast; Ductal carcinoma in situ; Low-risk; Radiotherapy; TamoxifenRadiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)journal article10.1186/s12885-023-11291-6377101982-s2.0-85171282358https://api.elsevier.com/content/abstract/scopus_id/85171282358